Lymphoma

Latest News

FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma
FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma

July 12th 2024

Michael Wang, MD, spoke about the recent liso-cel approval in mantle cell lymphoma and the TRANSCEND trial.

Findings from ELM-1 and ELM-2 support the positive opinion for odronextamab as a treatment for relapsed/refractory follicular lymphoma and DLBCL.
EU’s CHMP Recommends Odronextamab Approval in Follicular Lymphoma, DLBCL

July 1st 2024

EU’s CHMP Recommends Epcoritamab Approval in R/R Follicular Lymphoma | Image Credit: © Kateryna_Kon - stock.adobe.com.
EU’s CHMP Recommends Epcoritamab Approval in R/R Follicular Lymphoma

June 28th 2024

Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.
FDA Grants Accelerated Approval to Epcoritamab in R/R Follicular Lymphoma

June 26th 2024

Golidocitinib monotherapy had a superior clinical benefit in patients with relapsed/refractory peripheral T-cell lymphoma vs existing treatments.
Golidocitinib Receives Chinese Approval in Relapsed/Refractory PTCL

June 21st 2024

More News